Coconut, *Cocos nucifera* L., is a tree that is cultivated to provide a large number of products, although it is mainly grown for its nutritional and medicinal values. Coconut oil, derived from the coconut fruit, has been recognised historically as containing high levels of saturated fat; however, closer scrutiny suggests that coconut should be regarded more favourably. Unlike most other dietary fats that are high in long-chain fatty acids, coconut oil comprises medium-chain fatty acids (MCFA). MCFA are unique in that they are easily absorbed and metabolised by the liver, and can be converted to ketones. Ketone bodies are an important alternative energy source in the brain, and may be beneficial to people developing or already with memory impairment, as in Alzheimer’s disease (AD). Coconut is classified as a highly nutritious ‘functional food’. It is rich in dietary fibre, vitamins and minerals; however, notably, evidence is mounting to support the concept that coconut may be beneficial in the treatment of obesity, dyslipidaemia, elevated LDL, insulin resistance and hypertension – these are the risk factors for CVD and type 2 diabetes, and also for AD. In addition, phenolic compounds and hormones (cytokinins) found in coconut may assist in preventing the aggregation of amyloid-*β* peptide, potentially inhibiting a key step in the pathogenesis of AD.

The purpose of the present review was to explore the literature related to coconut, outlining the known mechanistic physiology, and to discuss the potential role of coconut supplementation as a therapeutic option in the prevention and management of AD.

**Key words:** Coconut; Saturated fat; Amyloid; Alzheimer’s; Diabetes

In line with the global predictions for the prevalence of Alzheimer’s disease (AD), Australia declared AD as the ninth National health priority in 2012. Alzheimer’s is a complex disease that progresses over many years, such as diabetes, heart disease and other chronic conditions. The gradual accumulation of the pathology of cerebral extracellular AD known as amyloid, which is mostly composed of aggregated amyloid-*β* (Aβ) peptides, as well as the accumulation of intracellular neurofibrillary tangles, appears to start up to 17–20 years before a clinically observable disease. A number of factors may increase or decrease an individual’s chances of developing the disease. These risk factors include age, genetics, environment, lifestyle and metabolic diseases.
Diet may play an important role in preventing AD. As many studies have linked AD risk to diet-modifiable conditions such as type 2 diabetes, hypertension and CVD, dietary approaches to AD prevention involving palatable, low risk, inexpensive substances are attracting great attention, as a method to ameliorating deficits concomitant with ageing and neurodegeneration. In particular, recent literature has suggested that the use of coconut oil (extra virgin/virgin), coconut water and coconut cream may have significant positive effects on the lowering of plasma cholesterol, blood pressure (BP) control and blood glucose levels, all of which are risk factors associated with AD. Coconut has also been identified as a potential cognitive strengtheners associated with AD. The present review reported the evidence for coconut oil consumption, with a particular emphasis on virgin coconut oil (VCO), outlining the potential risks and benefits in relation to AD prevention and/or management.

The scientific name for coconut is *Cocos nucifera*, and the plant is a member of the Arecaceae family [5–10]. Among the components of coconut, coconut oil is of the most interest related to human health. Of note, coconut oil is principally composed of SFA (about 92%), with 62–70% being medium-chain TAG (MCT) [4,11,12], making coconut oil unique among dietary fats. A few clinical trials and animal studies using a formulation of MCT have reported significant improvement of cognition in AD patients. While research on Alzheimer’s and MCT is still in its infancy, the science behind MCT is that MCT can be rapidly metabolised to induce metabolic ketosis and ketogenic, which could be employed as a therapy for a variety of brain disorders, including epilepsy and neurodegeneration. Anecdotes via the media and word-of-mouth have promoted great interest in the action of ketones and, thus, coconut oil.

Recent studies have investigated the possibility of using *trans*-zatin and phyto-oestrogen and other sex hormone-like substances present in coconut water and young coconut juice in reducing the risk of AD [13,14]. In contrast, experimental studies have suggested that coconut/coconut cream consumption can cause hyperlipidaemia and atherosclerosis, which are risk factors for AD. In contrast, several studies have reported that hyperlipidaemia and heart diseases are uncommon among high coconut consuming populations [15,16].

In view of the interest in the potential of coconut oil, coconut water and coconut cream as a dietary supplement that could ameliorate the symptoms of neurodegeneration, we analysed the literature to understand the influence of coconut on the pathology of AD and risk factors for AD. Adding complexity to this discussion is the various forms of coconut available, and also the method of extraction used to produce the end product.

**Coconut oil**

Coconut oil is extracted by either hot or cold pressed techniques, and the method used is reported to influence the quality and grade of the oil, although agreement on which method is best has not been achieved. Both wet and dry methods are used, and some approaches also involve solvents for the final extraction, if using coconut expeller cake [4]. VCO, manufactured using controlled temperature (hot or cold) methods are thought to be the most effective methods if aiming to retain the highest levels of biologically active components such as tocotrienols, tocopherols and sterols (phytosterols) [5]. This is in contrast to copra oil (derived from the dried coconut meat or kernel) that is processed with no temperature control [5,17]. VCO is natural, chemically unrefined and considered safe for human consumption [4]. Thus, in addition to being used as a cooking oil, VCO can also be considered as a functional food supplement. The total phenolic content of VCO (7.78–29.18 mg gallic acid equivalents/100 g oil) is significantly higher than that of refined coconut oil (6.14 mg gallic acid equivalents/100 g oil) [4,18]. However, there is no significant difference in fatty acid content among VCO, Copra and refined coconut oil, all containing 92% SFA, 6% MUFA and 2% PUFA. However, VCO has shown greater beneficial effects than copra oil in lowering lipid levels in serum and tissues and in reducing LDL oxidation by physiological oxidants. This property of VCO may be attributed to the biologically active polyphenol components present in the oil [19].

Not surprisingly, the high levels of saturated fat have generally deterred those who are more health conscious from using coconut oils, cream or milk. Furthermore, low-fat diets have been considered to be the best approach to reduce the risk of AD, in particular the Mediterranean diet [20,21]. Therefore, promoting coconut oil as a food would appear counter-intuitive. However, closer scrutiny of the chemical properties, digestion and uptake may suggest that this concern may not be well founded. Coconut oil is rich in medium-chain fatty acids (MCFA), which are metabolised differently to the long-chain fatty acids (LCFA) commonly found in human diets. In addition, coconut oil offers anti-ageing and anti-oxidant properties [22,23]. Coconut oil in food has a long history, and is very popular in South Asia and has a prominent place in Ayurvedic medicine.

**Coconut oil consists mostly of medium-chain fatty acids**

Coconut oil is principally composed of SFA (about 92%), with 62–70% being MCFA [4,11,12] (Table 1), making coconut oil

<table>
<thead>
<tr>
<th>Fatty acid</th>
<th>% Total fat</th>
<th>Saturated/unsaturated</th>
<th>MCFA/LCFA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caprylic (6:0)</td>
<td>0-6</td>
<td>Saturated</td>
<td>MCFA</td>
</tr>
<tr>
<td>Caprylic (8:0)</td>
<td>0-8</td>
<td>Saturated</td>
<td>MCFA</td>
</tr>
<tr>
<td>Capric (10:0)</td>
<td>6-4</td>
<td>Saturated</td>
<td>MCFA</td>
</tr>
<tr>
<td>Lauric (12:0)</td>
<td>46-5</td>
<td>Saturated</td>
<td>MCFA</td>
</tr>
<tr>
<td>Myristic (14:0)</td>
<td>17-6</td>
<td>Saturated</td>
<td>MCFA</td>
</tr>
<tr>
<td>Palmitic acid (16:0)</td>
<td>8-4</td>
<td>Saturated</td>
<td>MCFA</td>
</tr>
<tr>
<td>Stearic acid (18:0)</td>
<td>2-5</td>
<td>Saturated</td>
<td>LCFA</td>
</tr>
<tr>
<td>Linolenic acid (18:3)</td>
<td>6-5</td>
<td>Unsaturated</td>
<td>LCFA</td>
</tr>
<tr>
<td>Linoleic acid (18:2)</td>
<td>1-5</td>
<td>Unsaturated</td>
<td>LCFA</td>
</tr>
</tbody>
</table>

MCFA, medium-chain fatty acids; LCFA, long-chain fatty acids.
unique among dietary fats\(^{(5,11)}\). The difference between MCFA and LCFA is the length of the fatty acid carbon chain. MCFA have a chain length of six to twelve carbons\(^{(3,24)}\) (Table 1), whereas LCFA contain fourteen or more carbons\(^{(11,24)}\). The length of the carbon chain determines the physical and chemical properties of the fats as well as their metabolism in the human body\(^{(24)}\). Soya oil contains 60 % PUFA, 24 % MUFA and 16 % SFA\(^{(25)}\). In contrast, palm oil contains 50 % MUFA and 50 % SFA. This high level of PUFA of soya oil can improve the blood lipid profile status\(^{(20)}\). In addition, with its high content of tocopherols, soya oil is known to exhibit various antioxidant actions against lipid peroxidation.

**Metabolism of medium-chain fatty acids**

MCFA are broken down almost immediately by enzymes in the saliva and gastric juices, without the need for pancreatic fat-digesting enzymes\(^{(27)}\). Furthermore, this process involves relatively moderate energy consumption. Therefore, the metabolism of coconut oil is significantly different from that of other fatty acids commonly found in the diet\(^{(19)}\).

**Medium-chain fatty acid absorption**

In the case of most other fatty acids and cholesterol, the intestines play a major role in absorption\(^{(20)}\); yet unfortunately, pancreatic function declines with age, and therefore malabsorption problems can occur in patients who suffer from digestive and metabolic conditions. In other words, as the pancreatic output of digestive enzymes reduces, the efficiency of the small intestine in the absorption of nutrients diminishes\(^{(27–50)}\). This is important, as vitamin and mineral deficiencies are recognised as a global health issue\(^{(31)}\), and age-related changes and select disease processes exacerbate this problem\(^{(29,32,53)}\). As weight loss and malnutrition are recognised as frequent companions and contributors to AD, dietary supplementation with coconut oil may help prevent weight loss and increase the intake of certain vitamins and minerals.

The concern that coconut oil may increase plasma lipid levels and adversely affect health is a point of contention. MCFA are partially hydrolysed from dietary TAG by lingual lipase within the intestinal lumen\(^{(27)}\). Therefore, MCFA, other fats such as cholesterol, as well as saturated fat, monounsaturated fat and polyunsaturated fat containing LCFA, combine with proteins and form lipoproteins\(^{(24,27,53,54)}\). These lipoproteins enter the bloodstream via the lymphatic system, thus mostly bypassing the liver\(^{(27,55)}\). As lipoproteins circulate in the blood, their fatty components are dispersed to tissues\(^{(45)}\), therefore contributing to the accumulation of fat in such body tissues, as part of normal fat storage. However, in the process, some of these fats congeal within the artery walls, increasing the risk of hypertension and adding to the cardiovascular risk factors, and both known to increase AD risk\(^{(21)}\).

In contrast to LCFA that are easily esterified and bind strongly to fatty acid binding proteins\(^{(36,37)}\), MCFA are not easily esterified and resist binding. Thus, MCFA are less likely to contribute to such fat deposits, and thus have reduced impact on the cardiovascular system, including BP\(^{(34,55,38,39)}\). However, recent research with VCO has demonstrated that repeatedly heated VCO causes an elevation in BP. BP elevation has been associated with a significant increase in the inflammatory biomarkers (vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and C-reactive protein), thromboxane A\(_2\) and a significant reduction in the plasma PGI\(_2\) level\(^{(40)}\). Repeatedly heated soya oil and palm oil also elevated BP\(^{(41,42)}\).

**Medium-chain fatty acid breakdown**

Similar to the absorption differences mentioned above, the human body metabolises MCFA and LCFA via different pathways\(^{(33,43)}\). SCFA are transported in the blood as NEFA, while longer-chain NEFA are combined with albumin\(^{(11)}\). The metabolism of fatty acids is initiated on the outer mitochondrial membrane and is catalysed by acyl-CoA synthetase\(^{(43)}\) as shown in Fig. 1. This step is required partly to enable the transport of the fatty acids into the mitochondrial matrix. First, the fatty acid forms an acyl-adenylate; then while still tightly bound to the enzyme, acyl-adenylate is converted to acyl-CoA (medium-chain acyl-CoA or long-chain acyl-CoA) and AMP\(^{(45)}\). Acyl-CoA can then be transported into the mitochondria using different pathways depending on the fatty acid chain length\(^{(43)}\). Long-chain acyl-CoA molecules conjugate with carnitine (L-3-hydroxy-4-aminobutyrate or L-3-hydroxy-4-N-trimethylaminobutanoic acid, and its acyl-esters (acylcarnitines)\(^{43,44}\)) to form acylcarnitine, and this reaction is catalysed by carnitine acyltransferase\(^{\text{I}}\)\(^{(43)}\). In contrast, MCFA enter the mitochondria independently of the carnitine transport system\(^{(45)}\), and therefore do not depend on the activity of the carnitine acyltransferase-I enzyme, as with LCFA\(^{(45)}\). Medium-chain fatty acyl-CoA molecules easily transfer into the mitochondria and can then be converted into acetocetate (AcAc) and β-hydroxybutyrate, mainly by medium-chain fatty acyl-CoA-dehydrogenase\(^{(45)}\). These two products can be metabolised further in the liver to produce CO\(_2\), H\(_2\)O and energy\(^{(29,33,45)}\).

**Benefits of medium-chain fatty acids compared with long-chain fatty acids**

The result of the quicker metabolic conversion of MCFA is that instead of being deposited as fat, the energy generated from MCFA is very competently converted into fuel for immediate use by organs and muscles. Furthermore, MCFA produce 34·7 kJ/g (8·3 kcal/g) ingested, whereas LCFA will produce 38·5 kJ/g (9·2 kcal/g) ingested\(^{(40)}\). Thus, MCFA provide about 10 % less energy than LCFA. Although the difference sounds insignificant, this is just one of the many advantages of the human body metabolising MCFA and LCFA via different pathways\(^{(33,43)}\). SCFA are transported in the blood as NEFA, while longer-chain NEFA are combined with albumin\(^{(11)}\). The metabolism of fatty acids is initiated on the outer mitochondrial membrane and is catalysed by acyl-CoA synthetase\(^{(43)}\) as shown in Fig. 1. This step is required partly to enable the transport of the fatty acids into the mitochondrial matrix. First, the fatty acid forms an acyl-adenylate; then while still tightly bound to the enzyme, acyl-adenylate is converted to acyl-CoA (medium-chain acyl-CoA or long-chain acyl-CoA) and AMP\(^{(45)}\). Acyl-CoA can then be transported into the mitochondria using different pathways depending on the fatty acid chain length\(^{(43)}\). Long-chain acyl-CoA molecules conjugate with carnitine (L-3-hydroxy-4-aminobutyrate or L-3-hydroxy-4-N-trimethylaminobutanoic acid, and its acyl-esters (acylcarnitines)\(^{43,44}\)) to form acylcarnitine, and this reaction is catalysed by carnitine acyltransferase\(^{\text{I}}\)\(^{(43)}\). In contrast, MCFA enter the mitochondria independently of the carnitine transport system\(^{(45)}\), and therefore do not depend on the activity of the carnitine acyltransferase-I enzyme, as with LCFA\(^{(45)}\). Medium-chain fatty acyl-CoA molecules easily transfer into the mitochondria and can then be converted into acetocetate (AcAc) and β-hydroxybutyrate, mainly by medium-chain fatty acyl-CoA-dehydrogenase\(^{(45)}\). These two products can be metabolised further in the liver to produce CO\(_2\), H\(_2\)O and energy\(^{(29,33,45)}\).

**Fig. 1. Formation of acyl-CoA.**

\[
\text{Fatty acids + ATP \rightleftharpoons Acyl adenylate+PPI} \\
\text{Acyl adenylate +HS-CoA \rightleftharpoons Acyl CoA +AMP}
\]
MCFAs, as it will reduce obesity to some degree, and obesity is an independent risk factor for hypertension, hyperlipidaemia and diabetes, which are, in turn, the risk factors associated with AD. Differences between LCFA and MCFAs metabolism may also help in other more indirect ways in controlling obesity, and differences in the metabolism as well as the metabolic effects of LCFA and MCFAs have been demonstrated in both animal and human studies: for example, increases in post-prandial energy expenditure (EE) as well as the attenuation of weight accretion have been demonstrated, after short- or longer-term MCFAs consumption, and these are discussed below.

In early clinical studies, Flatt et al. compared diets rich in either MCFAs, LCFA or low in fats, and found that low-fat diets were most efficient for weight loss; however, they also found that MCFAs-rich diets may be better than LCFA-rich diets; this was supported by Hill et al. who reported that higher EE was achieved through MCFAs intake over 7 days when consumed in liquid formulation. This study demonstrated that excess dietary energy as MCFAs motivated thermogenesis to a higher degree than did excess energy as LCFA. This higher EE induced by MCFAs is most likely due to increased metabolic rates and thermogenesis. In a trial involving six participants, Scaife et al. introduced meals containing 30% fat, in the form of maize oil and animal fat, or MCFAs oil (56% octanoate and 40% decanoate), to evaluate EE. They found that EE after consumption of MCFAs (compared with LCFA) was 48% greater in lean individuals, and 65% greater in obese individuals. Dulloo et al. compared the effects of low-to-moderate amounts of MCFAs and LCFA consumption in eight healthy adult men. Subjects were given MCFAs and LCFA (30 g total) at (g%): 30, 5:25, 15:15 and 30:0, and their EE were measured. Increases in EE of 45, 135 and 265 kJ were achieved through MCFAs intake over 7 days when consumed in liquid formulation. This study demonstrated that excess dietary energy as MCFAs motivated thermogenesis to a higher degree than did excess energy as LCFA. This higher EE induced by MCFAs is most likely due to increased metabolic rates and thermogenesis.

Medium-chain fatty acids can be converted to ketone bodies

MCT or MCFAs can act as a non-carbohydrate fuel source by enhancing the formation of ketones or ketone bodies in the body, which are AcAc, 3-β-hydroxybutyrate (3HB) and acetone (24) (see Fig. 2). The first two molecules are used for energy production, whereas acetone is a breakdown product of AcAc. Fatty acids cannot pass the blood–brain barrier (BBB); thus, the human brain primarily depends on glucose. However, it can utilise alternative fuels such as monocarboxylic acids, lactate and ketones to maintain energy homeostasis (62,63), and ketone bodies are used extensively as an energy source during glucose deficiency (ketosis) (64,65). AcAc and 3HB are short-chain (four-carbon) organic acids (ketone bodies) that can cross cell membranes freely (64), and cross the BBB through proton-linked, monocarboxylic acid transporters (64).

Ketone bodies are absorbed by cells and converted back to acetyl-CoA, which enters the citric acid cycle (Krebs cycle) and is oxidised in the mitochondria to provide ATP (66) and also

\[ \text{Acetoacetate} \rightarrow \text{β-hydroxybutyrate} \rightarrow \text{Acetone} \]

Fig. 2. Ketone bodies.
precursors of acetylcholine in neurons. Alternatively, ketone bodies can be converted to acetyl-CoA in the brain for the purpose of synthesising LCFA.

**Ketogenic diets**

Diets that comprise very low carbohydrate levels, substantial amounts of protein and high fat levels have a capacity to result in the production of high levels of ketone bodies (3HB, AcAc and acetone) and are often known as ketogenic diets (KD). A KD has been found to be one of the most effective therapies for drug-resistant epilepsy; it has also provided specific benefits in conditions such as GLUT protein I deficiency, pyruvate dehydrogenase deficiency, myoclonic astatic epilepsy (Doose syndrome), tuberous sclerosis complex, Rett syndrome and severe myoclonic epilepsy in infancy (Dravet syndrome). Despite being used for many decades, the mechanism whereby a KD can reduce epilepsy is not understood. Recent research has suggested ketosis, reduced glucose, elevated fatty acid levels and enhanced bioenergetics reserves, as well as neuron-specific effects such as modulation of ATP-sensitive potassium channels, enhanced neurotransmission, increased brain-derived neurotrophic factor expression due to glycolytic restriction and reduced neuroinflammation may be involved.

Rats maintained on a KD display an altered influx of nutrients to the brain, due to the up-regulation of both ketone transporters and GLUT type 1. However, in early studies, it has also been found that the classic KD leads to a higher risk of atherosclerosis, a condition known to increase the risk of AD. More recent studies have indicated that the fatty acid content of the KD influences this risk of atherosclerosis: the classic KD contains a 4:1 or 3:1 ratio (by weight) of fat to combined protein and carbohydrate, with most of this fat being LCFA. Later studies have found that altered KD that are rich in MCTA, sometimes known as the MCT-KD, are more nutritionally adequate than classic KD, and are still effective in treating epilepsy disorders yet the MCT-KD contains less fat overall, as it includes MCFA from coconut oil that can provide a greater amount of ketone bodies per gram of fat and thus allows more carbohydrates and protein in the diet, making the diet more palatable than the classic KD. KD rich in MCFA have significant effects on lowering the cholesterol:HDL ratio compared with the classic KD.

The use of glucose for energy is vital in the brain; yet, this system is impaired in AD, partly due to disruption of the insulin signalling mechanism. Low glucose utilisation has been demonstrated in many studies by fluoro-2-deoxy- D-glucose positron emission tomography imaging in AD subjects. Importantly, this has also been detected in elderly people who later develop AD. In fact, the strikingly reduced expression in the central nervous system of genes encoding insulin, insulin like growth factor I (IGF-I) and insulin like growth factor II (IGF-II), as well as the insulin and IGF-I receptors, suggests that AD may represent a neuroendocrine disorder, which has been termed ‘Type 3 diabetes’. Since energy provision via glucose appears to be inadequate in emergent (pre-clinical) AD as well as established AD, it has been suggested that an enhanced supply of ketone bodies may be beneficial due to the resultant enhanced ATP output of mitochondria and fatty acid oxidation.

In support of this, a dual-tracer positron emission tomography study of rats on a KD showed that the diet caused increases in brain uptake of the two tracers C-13 AcAc and F-fluorodeoxyglucose S. Later studies by the same group have shown that a 14-d KD could increase the cerebral metabolic rate of AcAc and glucose by 28 and 44%, respectively, in aged (24-month) rats. Another recent pilot study, which investigated the effects of coconut oil supplementation directly on cortical neurons treated with...
Amyloid-(A) peptide in vitro, has indicated that neuron survival in cultures co-treated with coconut oil and Aβ is rescued compared with cultures exposed only to Aβ. Coconut oil co-treatment also attenuated Aβ-induced mitochondrial alterations. The results of this pilot study have provided a basis for further investigation of the effects of coconut oil, or its constituents, on neuronal survival, focusing on the mechanisms that may be involved. There are some contrasting results among the Animal studies. Van der Auwerda et al. reported a decrease of Aβ in the brain of young transgenic AD mice over expressing the London APP mutation fed with KD for 1.5 months, while study with aged dogs that has reported the effect of KD on Aβ is restricted to the parietal lobe of the brain. Kashiwaya et al. observed that long-term (8 months) feeding of a ketone ester in middle-aged mice (8-5 months old) improved cognition and reduced Aβ and τ pathology. Another study has demonstrated that AD mice model fed with a high-fat, low-carbohydrate KD shows improved motor function but without changes in Aβ. Providing further support for the benefits of high dietary MCFA levels against AD, an in vitro study demonstrated that the addition of ketone bodies (β-hydroxybutyrate) protects the hippocampal neurons from Aβ toxicity, thus suggesting possible therapeutic roles for KD on mitochondrial defects related to AD. Few studies have demonstrated that KD could significantly improve glucose homeostasis, reducing metabolic dysregulation and insulin resistance (IR), which is important to reduce the pathology of AD.

Morris et al. suggested that a high intake of unsaturated, unhydrogenated fats may be protective against AD, proposing that coconut oil may also be protective against AD. Despite the positive effect of KD, how the KD affects β-amyloid levels and whether this effect could be disease modifying in AD requires further study.

Adverse effects of ketones

There is a paucity of data on the adverse effects of ketone administration in the literature. A study has reported significant rise in the mean blood cholesterol level to over 2500 mg/l following a prolonged intake of a KD. This effect, in turn, may be atherogenic, leading to lipid deposition in blood vessels. Some researchers have observed dilated cardiomyopathy in patients on the KD, due to the toxic effects of elevated plasma NEFA. Further, an increased incidence in nephrolithiasis as well as increased in serum uric acid levels has been reported. Some side effects are common following administration of ketone bodies, such as dehydration and hypoglycaemia. However, growth retardation, obesity, nutrient deficiency, decreased bone density, hepatic failure and immune dysfunction are also observed, but not frequently.

Hiraide et al. reported a significant increase in pH and Na concentrations following the administration of a 20% solution of Na β-hydroxyl butyrate (BHB) to severe trauma patients. Also, reduction in glucose cerebral metabolism and the increase in cerebral blood flow were observed by Hasselbalch et al. during the administration of intravenous BHB. The long-term consequences of these deviations are not yet known.

KD with high-protein diets may cause possible kidney damage due to high levels of N excretion during protein metabolism. However, several researches have reported that even high levels of protein in the diet do not damage renal function. KD with very low carbohydrate can cause a regression of diabetic nephropathy due to acidosis. As the concentration of ketone bodies never rises above 8 mmol/l, this risk is minimum with normal insulin function subjects.

Coconut oil as a source of antioxidants

Antioxidants are substances of natural and synthetic origin that have a high potential to scavenge free radicals. The development of AD has been linked to oxidative stress, and studies have suggested that antioxidant-rich natural diets may protect against AD. Although studies on the benefits for AD have not been conclusive, many suggest that combinations of (rather than individual) antioxidants are beneficial. Coconut oil has a high percentage of phenolic acids, and these are phytochemicals, sometimes also referred to as polyphenols. Phenolic acids are recognised for their antioxidant properties. p-Coumaric acid, ferulic acid, caffeic acid and catechin acid are the major phenolic acids found in coconut oil. The hydroxyl group of phenolic compounds may be able to reduce the toxicity of the Alzheimer's Aβ peptide. In vitro studies that have investigated flavonoids indicate that the hydroxyl groups could trap hydrogen bonds of Aβ, which is important as this may reduce Aβ aggregation. It has also been shown that phenolic compounds can bind Aβ fibrils with their long axis parallel to the long axis of Aβ fibrils. Several other phenolic compounds have been shown to prevent Aβ aggregation and/or toxicity such as resveratrol, catechin and curcumin. However, despite the encouraging studies mentioned above, the exact mechanisms by which the phenolic group affects Aβ toxicity is not currently clear. While data from AD studies have suggested the beneficial effects of phenolic compounds on Aβ-related pathology, some discrepancies still exist. For example, recent work has demonstrated a significant inhibition of Aβ oligomers as well as higher growth of Aβ fibrils by phenolic compounds. These controversial results should be investigated further.

Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound that has potent antioxidant and anti-inflammatory activities. Ferulic acid, in particular, is one of the phenolic compounds demonstrated to have strong anti-Aβ aggregation properties. Researchers have found that the chronic administration of ferulic acid can reduce cortical levels of Aβ1–40 and Aβ1–42 as well as IL-1β levels in APP/PS1 AD-model transgenic mice. Ferulic acid has also been shown to inhibit Aβ deposition in the brain. However, another study has found that ferulic acid could not prevent the formation of Aβ fibrils, but could reduce the length of the fibrils. It appears that ferulic acid may be able to interrupt the elongation process...
by binding to the Aβ fibrils\(^{(120)}\). In other mouse studies, the long-term administration of ferulic acids could suppress the increase in glial fibrillar acidic protein and IL-1β immunoreactivity in the hippocampus that is induced by Aβ 1–42 treatment\(^{(130)}\).

p-Coumaric acid is another compound found in coconut oil that has high antioxidant capacity\(^{(131)}\). Maltolyl p-coumarate had been found to attenuate cognitive deficits in rat models and to cause a reduction in apoptotic cell death in the hippocampus of Aβ1–42-infused rats. All these studies have suggested that coconut oil contains many antioxidants with the potential to reduce the development of AD pathology.

**Coconut oil in insulin resistance and control of plasma lipids**

There are currently no effective AD treatments, and there is currently no cure on the immediate horizon. As mentioned earlier in this review, health issues, such as IR and obesity, similar to CVD, disrupted cholesterol metabolism, type 2 diabetes and hypertension, are all risk factors for AD\(^{(132,133)}\). Recent studies, many of which have already been mentioned, have shown that including coconut oil in the diet can reduce the risk of these factors, and due to the major disruption in insulin function that appears to happen early in the pathogenesis of AD, this aspect has gained particular attention.

IR is a condition where cells fail to respond to the normal actions of the hormone insulin\(^{(134)}\). This results in hyperinsulinemia that can eventually be diagnosed as type 2 diabetes. Insulin and insulin receptors have been reported to be enriched in brain areas where memory functions take place\(^{(134)}\). Therefore, impaired insulin regulation results in cognitive and memory shortfalls, such as those observed in AD patients as well as people with mild cognitive impairment\(^{(135)}\). Insulin is also an important regulator of proteins involved in the pathology of AD, namely the APP, and T\(^{(136)}\). Poor insulin action leads to poor regulation of brain glucose levels, which, in turn, can lead to an acceleration of neurodegeneration, due to oxidative stress and increased Aβ production from APP, both of which are key steps in the pathogenesis of AD\(^{(137)}\).

A higher rate of diabetes has developed in India and South Pacific Islands following dietary changes from traditional fats such as ghee and coconut oil to polyunsaturated fats such as sunflower or safflower oils\(^{(137)}\). Conversely, researchers have observed that a diet rich in coconut oil shields against IR in diabetic rats\(^{(138)}\). Furthermore, a more recent study has found that rats fed with LCFA and n-6 PUFA for 8 weeks induce IR, and increased the expression of liver X-receptors (LXα), carbohydrate response element binding protein and LCFA elongase-6 in the liver and white adipose tissue\(^{(139)}\). In contrast, the rats fed MCFa (from coconut oil) had reduced LXα, carbohydrate response element binding protein and LCFA elongase-6 expression as well as improved insulin signalling and less IR. In an in vitro study that compared LCFA and MCFa effects in myotubes, it has been found that MCFa-treated cells displayed less lipid accumulation, and MCFa increased the intrinsic respiratory capacity of mitochondria without increasing oxidative stress (less reactive oxygen species generation)\(^{(140)}\). Furthermore, in studies of thiazolidinediones, ligands that increase insulin sensitivity in type 2 diabetes via the PPARγ, it has been found that certain MCFa such as those in coconut oil (C8–C10) are low-potency agonists, yet without the deleterious side effects\(^{(141)}\). Such studies are beginning to characterise the mechanisms involved in the insulin signalling-protective effects of MCFa-containing diets. However, not all studies agree; for example, one study of male rats on a MCFa-rich diet has found that the diet causes increases in body adiposity and hyperinsulinemia and reduces insulin-mediated glucose uptake in the skeletal muscle\(^{(142)}\), indicating that further research is required to understand the metabolism and effects of different MCFa.

The major components in coconut oil that are believed to be involved in reducing IR are fatty acids (such as lauric acid (45–50 %) and capric acid) and phenolic compounds (such as ferulic acid and p-coumaric acid)\(^{(143,144)}\). Levels of the beneficial components are believed to be higher in VCO, which, as mentioned earlier, is prepared via a cold or low-heat-based extraction method. This oil contains higher levels of phenolic acids than copra or refined coconut oil\(^{(145)}\).

**Coconut oil and lipid metabolism**

The addition of VCO to the diet has also been associated with a decrease in plasma LDL-cholesterol (LDL-C) and TAG levels and an increase in HDL-cholesterol levels\(^{(146)}\). In this rat study, Nevin & Rajamohan\(^{(19)}\) demonstrated that VCO has a higher capacity to reduce serum LDL levels than copra oil, and to reduce LDL oxidation by physiological oxidants. Another study has concluded that coconut oil can lower cholesterol synthesis in human subjects, possibly due to lower production rates of apoB-containing lipoproteins\(^{(145)}\).

Abnormal metabolism of lipoproteins such as lipoprotein (a)/Lp(a) and their variants has been associated with peripheral artery disease, stroke, atherosclerosis, cerebrovascular disease as well as AD\(^{(146,147)}\). Coconut oil has been shown to help reduce Lp (a) levels, and the addition of coconut oil to the diet may improve cholesterol metabolism. In a study of twenty-five women, it has been observed that lipoprotein(a) levels are 13% lower after the women had consumed a high-fat diet containing coconut oil (38.4% of energy from fat)\(^{(25)}\). The same study has found that the postprandial plasma concentration of tissue plasminogen activator antigen (tPA antigen, often abnormally high in diabetes/IR)\(^{(148)}\), has dwindled when the women consumed the high-fat coconut diet, when compared with women who had consumed a diet high in unsaturated fat. Another study of women has noted that dietary coconut oil intake has been positively associated with HDL-cholesterol levels, especially among pre-menopausal women; the study has also found that coconut oil consumption did not cause a significant increase in LDL-C or TAG levels\(^{(149)}\). A meta-analysis\(^{(150)}\) of prospective epidemiological studies has demonstrated that dietary saturated fat is not associated with an increased risk of CHD or CVD. In contrast to these positive studies, Tsai et al\(^{(151)}\) reported that both MCT and lauric acid raised serum LDL-C concentrations compared with the more polyunsaturated...
baseline diet. Cater et al(152) also showed that MCT have one-half the potency that palmitic acid has at raising total and LDL-C concentrations. Interestingly, in 2004, Tholstrup et al(54) observed that MCFA had a hypercholesterolaemic effect. One study has noted that soya oil reduces cholesterol to a greater degree than coconut oil with no influence on HDL-cholesterol(153), and addition of Psyllium fibre supplementation lowers serum cholesterol regardless of saturation level of dietary fat(153). As cholesterol metabolism and AD pathology have been shown to be linked(147), further clinical research is required to understand the contribution of coconut oil to cholesterol metabolism and AD. Nevertheless, due to the many likely benefits of VCO, most researchers would recommend the inclusion of coconut oil in the diet; however, researchers are yet to decide how much coconut oil is required for optimal health. Two studies have recommended a daily intake of 3–5 tablespoons of VCO for a 72 kg man(154,155). This was based on the quantity of MCFA present in human breast milk. Interestingly, VCO and human breast milk have more saturated fats than mono- or poly-unsaturated fats, and in both cases, the main fat is lauric acid, with VCO containing the most, at about 50%(155). However, coconut dosage to enhance the memory of impaired people has not been concluded.

Apart from the benefits already mentioned above, both lauric acid, the main fatty acid in coconut, and phenolic compounds have anti-microbial or anti-bacterial properties. Thus, these compounds are considered to be protective against low-grade infections often associated with HT(127,130). Interestingly, specific fractions of coconut oil, extracted under hot conditions, have been shown to reduce blood glucose, cholesterol and lipid peroxidation, and some polyphenolic compounds appear to reduce liver lipid peroxidation(156,157).

Coconut oil and blood–brain barrier

The blood–brain barrier (BBB) is a brain endothelial structure of the fully differentiated neurovascular system(158) that protects the brain from foreign substances. It is noted that more than 98% of all small-molecule drugs, and approximately 100% of all large-molecule drugs or genes, do not cross the BBB(159). Thus, it is very difficult to develop effective new neurotherapeutics for AD that permeate the BBB. However, there is literature that indicates that circulating D-β-hydroxybutyrate ketone body, which is formed out of MCFA, crosses the BBB and enters the mitochondria where it is metabolised to AcAc and converted to acetyl-CoA, which enters into the Krebs cycle(160). One in vivo study with mice has identified the capacity of caprylic acid, a constituent of coconut oil, to cross the BBB. This study indicates that as a result of crossing the BBB, caprylic acid demonstrated anti-convulsant and a neuroprotective effect(161).

Coconut water

In countries where coconuts are a primary produce, coconut water is a common beverage. Coconut water contains a range of beneficial ingredients, including vitamins, minerals, antioxidants, amino acids, enzymes, growth factors and other nutrients(162). Cytokinins, a class of plant growth hormones (phytotrhomones) present in coconut water, influence plant cell division, and are considered to have anti-ageing properties(163,164). There are two types of cytokinins: adenine-type cytokinins (kinetin, zeatin and 6-benzylaminopurine) and phenylurea-type cytokinins (diphenylurea and thidiazuron). Recent studies have investigated the possibility of using trans-zeatin as a treatment drug for neuronal diseases including AD. Zeatin has demonstrated antioxidant and cell protective effects against Aβ-induced neurotoxicity in cultures of neuronal PC12 cells, and in experiments of mice treated with scopoline to induce amnesia, pretreatment of the mice with zeatin caused a reduction in the level of induced amnesia, according to the passive avoidance test and Y maze tes(165). Interestingly, another study has found that trans-zeatin could inhibit acetylcholinesterase(166,167). This indicates that cytokinin could have therapeutic value, as levels of the neurotransmitter acetylcholine are reduced in AD, and acetylcholinesterase inhibitors are currently used to ameliorate the symptoms of AD.

Coconut water has also been shown to have beneficial effects on serum and tissue lipid parameters, when given to rats concurrently fed a high-cholesterol containing diet(168). Another study has investigated the positive effect of regular consumption of two tropical food drinks, coconut (C. nucifera) water and mauby (Colubrina arborescens), on the control of hypertension(169). The combined products were found to be almost twice as effective as the products in isolation.

Other coconut food products

Apart from coconut water and extracted coconut oil, the coconut has a number of other culinary uses. The fleshy part of the seed, the coconut meat, can be used fresh or dried in cooking. Coconut cream and coconut milk are made by pressing the flesh to extract fluid, and these are used in many countries in cooking; for example, coconut milk is a component of many curries in India, Sri Lanka and other Asian countries. Desiccated coconut and coconut flour are also used in cooking and baking. Other products include coconut chips and flakes. Each of these products has a lipid (MCFA) component, and may also contain high levels of both soluble and insoluble fibre, as well as varying levels of the antioxidants and other beneficial components already mentioned above. Research has shown that many of these coconut products can improve lipid profiles as well as provide other benefits. For example, one study(170) has shown that the consumption of coconut milk does not elevate serum lipid levels, and another study(171) has found that a coconut milk porridge fed to sixty healthy people 5 d a week for 8 weeks caused a decrease in LDL levels and an increase in HDL levels. Further studies should be carried out to help validate these significant benefits of consuming coconut milk and cream, and to determine whether such benefits are counteracted by any unfavourable changes to serum lipid profiles. In another study(172), coconut flakes have been shown to reduce total cholesterol as well as LDL-C and serum TAG levels. Coconut residue after fluid extraction has a high percentage of soluble (3-41 g/100 g)
and insoluble (3±0 g/100 g) dietary fibre\textsuperscript{173}, and such high fibre content has been suggested to contribute to many of coconut's health benefits as in the coconut flake study mentioned above.

Salil et al.\textsuperscript{174}\textsuperscript{175} demonstrated an improvement in diabetic indicators following the consumption of coconut flesh; in this case, it is believed to be due to the protein content of coconut\textsuperscript{175}. The coconut kernel protein is rich in arginine, and the observed anti-diabetic activity of coconut flesh has been suggested to be due to the provision of arginine, which has been shown to influence pancreatic β cell regeneration\textsuperscript{174,175}. Similarly, another study has found that coconut water has a blood glucose-lowering effect and that coconut milk has a regenerative effect on the pancreatic cells damaged by diabetes\textsuperscript{87}. Arginine is a precursor of NO, produced by the endothelial isofrom of NO synthase, and NO is a signalling molecule that has a direct influence on insulin sensitivity. Maintaining NO production is also thought to be important in reducing cardiovascular complications of diabetes: arginine availability impacts on NO production, which can expand the blood vessels, allowing for the BP in the patients to be reduced\textsuperscript{176}.

## Conclusions

The consumption and use of coconut in its various forms has a long and established history in medicinal, scientific and nutritional arenas. While consumed prolifically in regions engaged in coconut primary production, Western cultures have tended to highlight the fatty acid content, particularly the saturated fat, and therefore limited its culinary usage.

The lipid content of coconut, being mostly MCFA, offers an energy source that bypasses the usual glucose pathway, in the form of ketone bodies, and without the associated fat deposition often caused by LCFA. Despite the positive effect of a KD, whether the KD influences β-amylloid levels and protects against AD requires further study. The dosage of ketones and the duration relevant to the AD also needs to be investigated. At this time, it is not clear whether ketone bodies produced from coconut oil has a direct effect on AD, specifically in relation to slowing or clearance of Aβ and τ pathologies – and if so, under what conditions. Furthermore, research needs to be conducted to quantify the yield of ketones from VCO, and support the ability of coconut derivatives to cross the BBB, to establish likely efficacy.

However, evidence to suggest that coconut may lower total and LDL-C, reduce systolic BP and ameliorate IR is of particular interest, in relation to AD risk reduction. A small number of clinical trials and animal studies using a formulation of MCT have reported significant improvement of cognition in AD patients. At the same time, studies in which the diet has been supplemented with SFA, particularly hydrogenated coconut oil, have reported deleterious effects on hippocampal morphology and behaviour, and increased plasma LDL levels.

Evidence suggests that despite coconut being a saturated fat, it may not pose the usual negative effects on lipid profiles; however, the influence on neuronal function and survival, as well as cardiovascular effects remains unknown. While the nutritional components of coconut are well accepted, inconsistencies in the data, it is suggested that further research needs to be undertaken before broadly advocating the use of coconut oil in addition to existing fat consumption or in substitution.

Coconut is, however, widely available, inexpensive, non-toxic and highly palatable, and consuming a regular intake of good quality coconut oil or another coconut product may become a simple yet important dietary change that may be shown in the future to reduce the risk of AD. However, research has suggested that the extraction method used to obtain VCO appears to affect the quality of coconut oil and may directly affect the efficacy. If specific extraction methods are essential to achieve efficacy, only particular preparations may confer benefit. Once this is known, further analysis needs to be undertaken regarding the absorption process, recommended dose, and whether it should be taken in combination with other food groups or in isolation.

It must be emphasised that the use of coconut oil to treat or prevent AD is not supported by any peer-reviewed large cohort clinical data; any positive findings are based on small clinical trials and on anecdotal evidence; however, coconut remains a compound of interest requiring further investigation.

## Acknowledgements

The authors gratefully acknowledge the support from the McCusker Alzheimer's Research Foundation and Edith Cowan University. W. M. A. D. B. F. is supported by the McCusker Alzheimer's Research Foundation and a grant from the CSIRO for the AIBL (The Australian Imaging, Biomarkers and Lifestyle) study. K. G. G. is supported by a grant from the Anglican Retirement Villages, Foundation for Aged Care and a grant from the CRC-Mental Health Limited. All authors contributed to the literature search, analysis of the data published, manuscript writing and revisions of the article. The authors declare no conflicts of interest arising from the conclusions of this research.

## References


https://doi.org/10.1017/S0007114515001452 Published online by Cambridge University Press


Dietary coconut may help fight Alzheimer's


Dietary coconut may help fight Alzheimer’s


